EQRx sells to another Alexis Borisy biotech after multiple pivots


The Cambridge startup that once intended to overhaul the biotech business model and make "radically" cheap drugs has ended in a sale.

Previous How Birmingham hospitals stack up in national U.S. News rankings
Next Orthopedic One eyes relocation of Columbus office to new $20M building at Gahanna's Crescent at Central Park development